Recombinant human erythropoietin use in hemolytic anemia due to prosthetic heart valves: a promising treatment.
Two patients are reported with hemolytic anemia due to red blood cell fragmentation in association with prosthetic heart vales. They were treated with erythropoietin which eliminated the need for packed red blood cell transfusion.
Don Monti Division of Medical Oncology, Department of Medicine, North Shore University Hospital-New York University School of Medicine, Manhasset, New York 11030, USA.
S
S
Hirawat
S M
SM
Lichtman
S L
SL
Allen
D000368:Aged; D000743:Anemia, Hemolytic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008943:Mitral Valve; D011994:Recombinant Proteins; D017701:Reticulocyte Count
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin